Twelve months, twelve people, zero decline

Twelve people took a daily pill for a year. Twelve months later, their Parkinson's motor scores hadn't budged — no decline, no progression, no significant safety flags. For a disease with no treatment that slows it down, standing still is the win that Gain Therapeutics' rexaceract just delivered in its Phase 1b extension, presented this week at the movement-disorders congress in Seoul.